Enbrel (etanercept) is a fully human soluble Tumour Necrosis Factor (TNF) receptor protein, indicated to treat; rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis1
Pfizer is committed to using our extensive experience to support and transform the lives of patients living with debilitating inflammatory diseases. Take a look at our Inflammation page to see how we have supported patients for over 20 years.
Take a look at Enbrels efficacy and safety information when treating Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Non-radiographic axial spondyloarthritis, Plaque psoriasis, Paediatric plaque psoriasis1
Learn about the recommended dosing for Enbrel and the devices available to your patients to help their at-home management
See what online support your patients have access to
To keep up to date on NICE guidance. See NICE guidance on Enbrel.
Learn details about the European Public Assessment report (EPAR) for Enbrel.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021